A Phase 1/1b Study to Evaluate the Safety and Tolerability of AB801 Monotherapy and Combination Therapy in Participants With Advanced Malignancies
NCT #
not yet registered
Condition(s)
Lung Cancer (NSCLC)
Molecular Target(s)
AXL, PD-1
Drug Classification(s)
Immunotherapy, Monoclonal Antibody (Immunotherapy, Small Molecule (Targeted), targeted
Agents(s)
AB801
Phase(s)
I
Mechanism of Action
AB801 is an AXL inhibitor
Purpose
- The purpose of the study is to determine whether an experimental drug called AB801 is safe and effective when given alone or in combination with other therapies to patients with the type of cancer you have.
- In addition to assessing how safe and well tolerated AB801 is, the study will be measuring the amount of AB801 in your bloodstream and monitoring your body’s response to receiving this drug.
Location
MCD
Connect With Us
Whether you want to give a spark of hope or you are looking for it, we are here to help. If you have any questions or concerns, please contact us here.